Ocular Therapeutix™ To Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on Apri...
23 March 2018 - 7:36AM
Business Wire
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced it will be featured as a
presenting company at the H. C. Wainwright Annual Global Life
Sciences Conference on April 8-10 at the Le Meridien Beach Plaza
Hotel in Monte Carlo, Monaco.
Antony Mattessich, President and Chief Executive Officer of
Ocular Therapeutix, will deliver a live presentation on the
Company's pipeline and business activities and will be available to
participate in one-on-one meetings with investors registered to
attend the conference.
If you are an institutional investor, and would like to attend
the Company’s presentation, please click on the following link to
register for the conference (www.hcwevents.com). Once your
registration is confirmed, you will be prompted to log into the
conference website to request a one-on-one meeting with the
Company.
Event: H. C. Wainwright Annual Global Life
Sciences Conference
Presentation Date: April 9, 2018
Presentation Time: Monday, 2:35PM UTC
Location: Salon Atlantique; Le Meridien Beach
Plaza Hotel in Monte Carlo, Monaco
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused
on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary hydrogel-based formulation technology. Ocular
Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone
insert) 0.4 mg for intracanalicular use, has completed Phase 3
clinical development for the treatment of ocular pain and
inflammation following ophthalmic surgery. OTX-TP (travoprost
insert) is in Phase 3 clinical development for the reduction of
intraocular pressure in patients with glaucoma and ocular
hypertension. The Company’s earlier stage assets include OTX-TIC, a
sustained release travoprost intracameral implant for the reduction
of intraocular pressure in patients with glaucoma and ocular
hypertension, as well as sustained release intravitreal implants
for the treatment of retinal diseases. These implants include the
development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in
collaboration with Regeneron, an extended release protein-based
anti-vascular endothelial growth factor (VEGF) trap. Ocular
Therapeutix's first product, ReSure® Sealant, is FDA-approved to
seal corneal incisions following cataract surgery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180322006265/en/
InvestorsOcular TherapeutixDonald NotmanChief Financial
Officerdnotman@ocutx.comorWestwicke PartnersChris BrinzeyManaging
Directorchris.brinzey@westwicke.comorMediaOcular
TherapeutixScott CorningSenior Vice President,
Commercialscorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Apr 2024 to May 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From May 2023 to May 2024